JP2009518394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518394A5 JP2009518394A5 JP2008544296A JP2008544296A JP2009518394A5 JP 2009518394 A5 JP2009518394 A5 JP 2009518394A5 JP 2008544296 A JP2008544296 A JP 2008544296A JP 2008544296 A JP2008544296 A JP 2008544296A JP 2009518394 A5 JP2009518394 A5 JP 2009518394A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- esomeprazole
- salt
- amine
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 9
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 claims 8
- 229960004770 esomeprazole Drugs 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000006011 modification reaction Methods 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 150000001412 amines Chemical group 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 159000000001 potassium salts Chemical group 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (16)
- 以下の工程：
ｉ）エソメプラゾールの塩基付加塩を、少なくとも１種のアミンＢ1を含む水に溶解させること；
ii）少なくとも１種の酸ＨＡ1を添加すること；
iii）エソメプラゾールの非塩形態を結晶化させ、形成された結晶を単離すること、を実質的に含む、エソメプラゾールの非塩形態の製造方法。 - 塩基付加塩は、カリウムまたはナトリウム塩である、請求項１に記載の方法。
- アミンＢ1は、有機アミンまたはアンモニアである、請求項１に記載の方法。
- アミンＢ1は、アンモニア、トリエチルアミン、メチルアミン、エチレンジアミン、エタノールアミン、ジエタノールアミン、トリメチルアミン、ジエチルアミン、または、ジメチルアミンである、請求項１に記載の方法。
- 酸ＨＡ1は、有機酸、または、鉱酸である、請求項１に記載の方法。
- 酸ＨＡ1は、クエン酸、炭酸水素ナトリウム、炭酸、塩酸、または、酢酸のいずれかである、請求項１に記載の方法。
- 工程ii）後のｐＨは、約８〜９である、請求項１に記載の方法。
- 工程ii）で添加された酸ＨＡ1の量は、約０.２〜０.８モル当量である、請求項１に記載の方法。
- 酸は、水溶液として添加される、請求項１に記載の方法。
- 周囲温度で行われる、請求項１に記載の方法。
- 約１０℃で行われる、請求項１に記載の方法。
- 実質的に図２で定義されたエソメプラゾールの非塩型の変態Ｃ。
- 実質的に図３で定義されたエソメプラゾールの非塩型の変態Ｅ。
- 実質的に図４で定義されたエソメプラゾールの非塩型の変態Ｇ。
- 医療に使用するための、請求項１２〜１４のいずれか一項で定義されたエソメプラゾールの非塩型の変態。
- 請求項１２〜１４のいずれか一項で定義されたエソメプラゾールの非塩型の治療有効量を、それを必要とする患者に投与することを含む、治療方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74229605P | 2005-12-05 | 2005-12-05 | |
| PCT/SE2006/001381 WO2007067128A1 (en) | 2005-12-05 | 2006-12-04 | New process for the preparation of esomeprazole non-salt form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518394A JP2009518394A (ja) | 2009-05-07 |
| JP2009518394A5 true JP2009518394A5 (ja) | 2009-12-24 |
Family
ID=38123162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544296A Pending JP2009518394A (ja) | 2005-12-05 | 2006-12-04 | エソメプラゾールの非塩形態の新規の製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8124779B2 (ja) |
| EP (1) | EP1960384A4 (ja) |
| JP (1) | JP2009518394A (ja) |
| KR (1) | KR20080076924A (ja) |
| CN (1) | CN101321746A (ja) |
| AU (1) | AU2006323245B2 (ja) |
| BR (1) | BRPI0619158A2 (ja) |
| CA (1) | CA2631919A1 (ja) |
| IL (1) | IL191547A0 (ja) |
| NO (1) | NO20083028L (ja) |
| NZ (1) | NZ568471A (ja) |
| WO (1) | WO2007067128A1 (ja) |
| ZA (1) | ZA200804778B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
| US9356980B2 (en) | 2012-07-31 | 2016-05-31 | At&T Intellectual Property I, L.P. | Distributing communication of a data stream among multiple devices |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB9105031D0 (en) * | 1991-03-09 | 1991-04-24 | Fisons Plc | Processing analytical reagents |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| DE29522419U1 (de) | 1994-07-08 | 2003-07-03 | AstraZeneca AB, Södertälje | Tablettierte Mehrfacheinheits-Dosisform |
| SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| AU733552B2 (en) | 1996-12-20 | 2001-05-17 | Altana Pharma Ag | Imidazopyridazines |
| US6586259B1 (en) * | 1999-11-15 | 2003-07-01 | Pharmanetics Incorporated | Platelet/leukocyte interaction assay and reagent therefor |
| RU2394022C2 (ru) * | 2002-03-04 | 2010-07-10 | МЕРК ЭйчДиЭйСи Рисерч, ЛЛС | Способы индукции конечной дифференцировки |
| EA200500673A1 (ru) | 2002-10-22 | 2005-12-29 | Рэнбакси Лабораториз Лимитед | Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе |
| US7678816B2 (en) * | 2003-02-05 | 2010-03-16 | Teva Pharmaceutical Industries Ltd. | Method of stabilizing lansoprazole |
| RU2005129513A (ru) * | 2003-02-28 | 2006-03-10 | Рэнбакси Лабораториз Лимитед (In) | Полиморфы s-омепразола |
| CN1197861C (zh) * | 2003-06-10 | 2005-04-20 | 中国科学院成都有机化学研究所 | 固态光学纯中性的s－（－）－和r－（+）－奥美拉唑的制备方法 |
| EP1522594A3 (en) * | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| JP2008503493A (ja) * | 2004-06-17 | 2008-02-07 | アナザオヘルス コーポレーション | 腫瘍を破壊するための安定化され凍結乾燥された放射性薬剤 |
| KR100641534B1 (ko) * | 2005-07-28 | 2006-11-01 | 한미약품 주식회사 | 에스오메프라졸 및 그의 염의 제조방법 |
| US20070065893A1 (en) * | 2005-09-19 | 2007-03-22 | Carol Carte | Liquid-phase galactose oxidase-schiff's assay |
| US8030010B2 (en) * | 2005-10-14 | 2011-10-04 | Institut De Cardiologie De Montreal | Method for detecting a biomarker of oxidative stress in a biological sample |
| US7906293B2 (en) * | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
-
2006
- 2006-12-04 AU AU2006323245A patent/AU2006323245B2/en not_active Ceased
- 2006-12-04 BR BRPI0619158-4A patent/BRPI0619158A2/pt not_active IP Right Cessation
- 2006-12-04 JP JP2008544296A patent/JP2009518394A/ja active Pending
- 2006-12-04 WO PCT/SE2006/001381 patent/WO2007067128A1/en active Application Filing
- 2006-12-04 CN CNA2006800456075A patent/CN101321746A/zh active Pending
- 2006-12-04 CA CA002631919A patent/CA2631919A1/en not_active Abandoned
- 2006-12-04 EP EP06824511A patent/EP1960384A4/en not_active Withdrawn
- 2006-12-04 KR KR1020087013453A patent/KR20080076924A/ko not_active Application Discontinuation
- 2006-12-04 NZ NZ568471A patent/NZ568471A/en not_active IP Right Cessation
- 2006-12-04 US US12/096,199 patent/US8124779B2/en not_active Expired - Fee Related
-
2008
- 2008-05-19 IL IL191547A patent/IL191547A0/en unknown
- 2008-06-02 ZA ZA200804778A patent/ZA200804778B/xx unknown
- 2008-07-04 NO NO20083028A patent/NO20083028L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| AR068527A2 (es) | Un procedimiento para preparar monohidrato de bromuro de tiotropio cristalino | |
| JP2009517023A5 (ja) | ||
| ES2324665T3 (es) | Proceso farmaceutico y compuestos preparados a traves del mismo. | |
| PE20081258A1 (es) | ANTICUERPOS ANTI-hTNFALFA CRISTALINOS | |
| PE20090646A1 (es) | Sales de n-[2-(dietilamino)etil]-n-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida | |
| RU2017109814A (ru) | Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота | |
| PE20061014A1 (es) | Clorhidrato de lercanidipina amorfo | |
| BRPI0310118B1 (pt) | processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila | |
| ES2278552T1 (es) | Preparacion de intermediarios de tadalafil. | |
| RU2007145207A (ru) | Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции | |
| NO20055257L (no) | Ny fremgangsmate for syntesen av s-indolin-2-karboksylsyre og anvendelse derav i syntesen av perindopril | |
| JP2009518394A5 (ja) | ||
| SMAP200900080A (it) | Sali di addizione acida, idrati e polimorfi di acido 5-(2,4-diidrossi-5-isopropil-fenil)-isossazolo-3-carbossilico etilammide e formulazioni comprendenti queste forme | |
| JP2009040767A5 (ja) | ||
| AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| EA200801960A1 (ru) | Соли дулоксетина | |
| BRPI0512151A (pt) | solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol | |
| JP2004536810A5 (ja) | ||
| ATE486867T1 (de) | Verfahren zur herstellung von hochreinem meloxicam und meloxicam-kaliumsalz | |
| JP2008125364A5 (ja) | ||
| UA106580C2 (uk) | Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва | |
| CY1114768T1 (el) | Μεθοδος για την παρασκευη αμορφης υδροχλωρικης λερκανιδιπινης | |
| DE602006008335D1 (de) | Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen | |
| ATE509619T1 (de) | Herstellungsverfahren für eine feste dispersion mit itraconazol |